Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14432747 | 1.00 | KIF11 (1.00) | KIF11DNMT1 | |
| SCHEMBL14432746 | 1.00 | KIF11 (1.00) | KIF11DNMT1 | |
| SCHEMBL14432855 | 0.91 | KIF11 (0.83) | KIF11DNMT1 | |
| SCHEMBL14432853 | 0.91 | KIF11 (0.83) | KIF11DNMT1 | |
| SCHEMBL15848679 | 0.90 | KIF11 (0.80) | KIF11DNMT1 | |
| SCHEMBL15848702 | 0.90 | KIF11 (0.80) | KIF11DNMT1 | |
| S-Trityl-L-Cysteine SCHEMBL768202 | 0.87 | KIF11 (0.85) | KIF11DNMT1 | |
| S-Trityl-L-Cysteine SCHEMBL768203 | 0.87 | KIF11 (0.85) | KIF11DNMT1 | |
| S-Trityl-L-Cysteine SCHEMBL6891349 | 0.87 | KIF11 (0.85) | KIF11DNMT1 | |
| SCHEMBL31438660 | 0.87 | KIF11 (0.77) | KIF11DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038669-A1 | BICYCLIC MIMICS-RIGID, CELL PERMEABLE, SERUM STABLE HELICAL MIMICS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2025-02-20 | — | — | WO | disclosed |
| US-12227542-B2 | Method for producing peptide compound, protective group-forming reagent, and condensed polycyclic compound | FUJIFILM CORPORATION (JP) | 2025-02-18 | — | — | US | disclosed |
| CN-114524860-B | ETELCALCETIDE synthesis method and application thereof | 深圳翰宇药业股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240336655-A1 | AMPHIPHILIC PEPTIDES FOR NUCLEIC ACID AND PROTEIN DELIVERY | AJK BIOPHARMACEUTICAL LLC (US) | 2024-10-10 | — | — | US | disclosed |
| US-20240033372-A1 | MULTI-DRUG ANTIBODY DRUG CONJUGATES | SEAGEN INC (US) | 2024-02-01 | — | — | US | disclosed |
| US-20240002432-A1 | METHOD FOR PRODUCING AMINO ACID OR PEPTIDE, PROTECTIVE GROUP-FORMING REAGENT, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2024-01-04 | — | — | US | disclosed |
| WO-2023014909-A1 | AMPHIPHILIC PEPTIDES FOR NUCLEIC ACID AND PROTEIN DELIVERY | AJK Biopharmaceutical, LLC (US) | 2023-02-09 | — | — | WO | disclosed |
| CN-110317188-B | Compound and preparation method and application thereof | 深圳翰宇药业股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-20230000999-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID DELIVERY | PARANG KEYKAVOUS (US) | 2023-01-05 | — | — | US | disclosed |
| US-11541128-B2 | Multi-drug antibody drug conjugates | SEAGEN INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-2571496-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | Prolynx Llc (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2566334-A1 | CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS | Prolynx Llc (US) | 2013-03-13 | — | — | EP | disclosed |
| US-8349899-B1 | Selective inhibitors of EG5 motors and methods of use | ARROWHEAD CENTER, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349899-B1 | Selective inhibitors of EG5 motors and methods of use | ARROWHEAD CENTER, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349899-B1 | Selective inhibitors of EG5 motors and methods of use | ARROWHEAD CENTER, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| WO-2011140376-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140392-A1 | CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| EP-1087992-B1 | ANTITHROMBOTIC COMPOUNDS | ORGANON NV (NL) | 2008-08-20 | — | — | EP | disclosed |
| EP-1087992-A1 | ANTITHROMBOTIC COMPOUNDS | Akzo Nobel N.V. (NL) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065934-A1 | ANTITHROMBOTIC COMPOUNDS | AKZO NOBEL N.V. (NL) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227542-B2 | Method for producing peptide compound, protective group-forming reagent, and condensed polycyclic compound | C9, GRPR, VIP | KIF11 3303/4885DNMT1 3331/4885 |
| US-20240336655-A1 | AMPHIPHILIC PEPTIDES FOR NUCLEIC ACID AND PROTEIN DELIVERY | LNPEP, ZFR, SREBF1 | KIF11 1634/4885DNMT1 1747/4885 |
| US-20240002432-A1 | METHOD FOR PRODUCING AMINO ACID OR PEPTIDE, PROTECTIVE GROUP-FORMING REAGENT, AND COMPOUND | NGLY1, VIP, FPR1 | KIF11 4721/4885DNMT1 4145/4885 |
| US-20240033372-A1 | MULTI-DRUG ANTIBODY DRUG CONJUGATES | CDA, DCTD, MMAB | KIF11 424/4885DNMT1 107/4885 |
| US-20230000999-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID DELIVERY | ARGLU1, SLC7A11, PNISR | KIF11 1611/4885DNMT1 1416/4885 |
| US-11541128-B2 | Multi-drug antibody drug conjugates | CDA, DCTD, MMAB | KIF11 443/4885DNMT1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.